一分钟看懂
这是一项关于晚期实体瘤的II 期研究，登记的药物或干预包括HER3-DXd，当前状态为招募中。登记地点显示中国成都、广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HER3-DXd · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- West China Hospital, Sichuan University · 成都
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- Participants must meet all of the following criteria to be eligible for enrollment into the study:
- 1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.
- 2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
- 3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:
- Cutaneous (acral and non-acral) melanoma
- 1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma
- 2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \[ICIs\] \[ie, anti-C
- Squamous cell carcinomas of the head and neck
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06172478；登记信息更新于 2026-09-17。